Upstream Bio, Inc.
UPB· Nasdaq
Released Aug 11, 2026, before the open
10-Q filed Aug 11, 2026, 42 days after period end · 0001193125-26-343417
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $773.00K | $937.00K | $510.00K | — |
| Net Income | -$39.70M | -$39.97M | -$14.68M | -$2.54M |
| EPS Diluted |
Upstream Bio, Inc. · CIK 2022626 · Engraved from SEC EDGAR
| -$0.73 |
| -$0.74 |
| -$6.50 |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.